An Evolutionary Stress-Response Hypothesis for Chronic Widespread Pain (Fibromyalgia Syndrome)

Pain Medicine

Volumn 12, Issue 8, 2011, Pages 1167-1178

  Lyon, Pamela ^a   Cohen, Milton ^b   Quintner, John ^c  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b Fremantle Hospital ^*  (Australia)

^c FREMANTLE HOSPITAL   (Australia)

Author keywords

Central Sensitization; Evolutionary Biology; Fibromyalgia; Neurokinin 1 Receptor; Stress Response; Substance P

Indexed keywords

METENKEPHALIN; NEUROKININ 1 RECEPTOR; STRESS HORMONE; SUBSTANCE P;

CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; CLINICAL FEATURE; COGNITION; FIBROMYALGIA; HOMEOSTASIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MENTAL STRESS; MORBIDITY; NOCICEPTION; NONHUMAN; PATHOGENESIS; POSTTRAUMATIC STRESS DISORDER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEXUAL ABUSE; SIGNAL TRANSDUCTION; STRESS; UPREGULATION;

EID: 80051682574     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01168.x     Document Type: Review

References (155)

1. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2, 596 people with fibromyalgia. BMC Musculoskelet Disord 2007;8:27.
2. Spaeth M. Epidemiology, costs, and the economic burden of fibromyalgia. Arthritis Res Ther 2009;11:117.
3. Wolfe F. Fibromyalgia wars. J Rheumatol 2009;36(4):671-8.
4. Wolfe F, Smythe HA, Yunus MB, etal. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990;33:160-72.
5. Hart BL. Biological basis of the behavior of sick animals. Neurosc Biobehav Rev 1988;12:123-37.
6. Watkins L, Maier S. Immune regulation of central nervous system functions: From sickness responses to pathological pain. J Intern Med 2005;257:139-55.
7. Meeus M, Nijs J. Central sensitization: A biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol 2007;26:465-73.
8. Yunus MB. Central sensitivity syndromes: A new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum 2008;37:339-52.
9. Ji R-R, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: Do pain and memory share similar mechanisms? Trends Neurosci 2003;26:696-705.
10. Latremoliere A, Woolf CJ. Central sensitization: A generator of pain hypersensitivity by central neural plasticity. J Pain 2009;10:895-926.
11. Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science 2000;288:1765-9.
12. Torpy DJ, Papanicolaou DA, Lotsikas AJ, etal. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: A pilot study in fibromyalgia. Arthritis Rheum 2000;43:872-80.
13. McLean S, Clauw D, Abelson J, Liberzon I. The development of persistent pain and psychological morbidity after motor vehicle collision: Integrating the potential role of stress response systems into a biopsychosocial model. Psychosom Med 2005;67:783-90.
14. Chapman CR, Tuckett RP, Song CW. Pain and stress in a systems perspective: reciprocal neural, endocrine, and immune interactions. J Pain 2008;9(2):122-45.
15. Martinez-Lavin M, Vargas A. Complex adaptive systems in fibromyalgia. Rheum Dis Clin North Am 2009;35:285-98.
16. Crofford LJ, Clauw DJ. Fibromyalgia: Where are we a decade after the American College of Rheumatology classification criteria were developed? Arthritis Rheum 2002;46:1136-8.
17. Khasabov SG, Rogers SD, Ghilardi JR, etal. Spinal neurons that possess the Substance P receptor are required for the development of central sensitization. J Neurosci 2002;22:9086-98.
18. Bertalanffy LV. The theory of open systems in physics and biology. Science 1950;111(2872):23-9.
19. Maturana HR, Varela FJ. Autopoiesis: The organization of the living. In: Maturana HR, Varela FJ, eds. Autopoiesis and Cognition: The Realization of the Living. Vol 42.Dordrecht: D. Reidel Publishing Company; 1980:59-138.
20. Cannon WB. The Wisdom of the Body. Reprint [1939] Ed. London: Kegan Paul, Trench, Trubner; 1947.
21. Lyon PL. The agent in the organism: Toward a biogenic theory of cognition. PhD thesis. Canberra: The Australian National University; 2006.
22. Shapiro JA, Dworkin M, eds. Bacteria As Multicellular Organisms. New York and Oxford: Oxford University Press; 1997.
23. Selye H. The Stress of Life. New York: McGraw-Hill Inc.; 1956.
24. Chrousos GP, Gold PW. The concepts of stress and stress system disorders: Overview of physical and behavioral homeostasis. JAMA 1992;267:1244-52.
25. Storz GT, Hengge-Aronis R. Bacterial Stress Responses. Washington, DC: ASM Press; 2000.
26. Aertsen A, Michiels CW. Stress and how bacteria cope with death and survival. Crit Rev Microbiol 2004;30:263-73.
27. Juster R-P, McEwen BS, Lupien SJ. Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci Biobehav Rev 2010;35:2-16.
28. Calabrese E, Mehendale H. A review of the role of tissue repair as an adaptive strategy: Why low doses are often non-toxic and why high doses can be fatal. Food ChemToxicol 1996;34:301-11.
29. Calabrese EJ, Baldwin LA. Hormesis as a biological hypothesis. Environ Health Perspect 1998;106(suppl 1):357-62.
30. McFarlane AC. The long-term costs of traumatic stress: Intertwined physical and psychological consequences. World Psychiatry 2010;9:3-10.
31. Wingfield JC. Control of behavioural strategies for capricious environments. Anim Behav 2003;66:807-16.
32. Black PH, Garbutt LD. Stress, inflammation and cardiovascular disease. J Psychosom Res 2002;52:1-23.
33. Otting N, Heijmans CMC, Noort RC, etal. Unparalleled complexity of the MHC class I region in rhesus macaques. PNAS 2005;102:1626-31.
34. von Euler U, Gaddum J. An unidentified depressor substance in certain tissue extracts. J Physiol (London) 1931;72:74-87.
35. O'Connor TM, O'Connell J, O'Brien DI, etal. The role of substance P in inflammatory disease. J Cell Physiol 2004;201:167-80.
36. Hoheisel U, Mense S, Ratkai M. Effects of spinal cord superfusion with substance P on the excitability of rat dorsal horn neurons processing input from deep tissues. J Musculoskelet Pain 1995;3:23-43.
37. Mayer ML, MacLeod NK. The excitatory action of substance P and stimulation of the stria terminalis bed nucleus on preoptic neurones. Brain Res 1979;166:206-10.
38. Langosch JM, Kupferschmid S, Heinen M, etal. Effects of substance P and its antagonist L-733060 on long term potentiation in guinea pig hippocampal slices. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:315-9.
39. Lembeck F. A network of defense. In: Henry J, Couture R, Cuellot A, eds. Substance P and Neurokinins. New York: Springer-Verlag; 1987:380-7.
40. Berczi I, Chalmers IM, Nagy E, Warrington RJ. The immune effects of neuropeptides. Baillieres Clin Rheumatol 1996;10:227-57.
41. Payan D. Neuropeptides and inflammation: The role of substance P. Annu Rev Med 1989;40:341-52.
42. Mantyh PW. Neurobiology of substance P and the NK1 receptor. J Clin Psychiatry 2002;63(suppl 11):6-10.
43. Elde R, Hokfelt T. Localization of hypophysiotropic peptides and other biologically active peptides within the brain. Annu Rev Physiol 1979;41:587-602.
44. Nicoll RA, Schenker C, Leeman SE. Substance P as a transmitter candidate. Anu Rev Neurosci 1980;3:227-68.
45. Vlaeyen J, Linton S. Fear-avoidance and its consequences in chronic musculoskeletal pain: A state of the art. Pain 2000;85:317-32.
46. Eriksen HR, Murison R, Pensgaard AM, Ursin H. Cognitive activation theory of stress (CATS): From fish brains to the Olympics. Psychoneuroendocrinology 2005;30:933-8.
47. Hasenöhrl RU, Gerhardt P, Huston JP. Evidence for dose-dependent positively and negatively reinforcing effects of the substance P C-terminal analog DIME-C7. Neuropeptides 1990;17:205-11.
48. Felipe CD, Herrero JF, O'Brien JA, etal. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 1998;392:394-7.
49. Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 2006;31:251-72.
50. Bilkei-Gorzo A, Racz I, Michel K, Zimmer A. Diminished anxiety- and depression-related behaviors in mice with selective deletion of the Tac1 gene. J Neurosci 2002;22:10046-52.
51. Commons K. Neuronal pathways linking substance P to drug addiction and stress. Brain Res 2010;1314:175-82.
52. Levick SP, Murray DB, Janicki JS, Brower GL. Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. Hypertension 2010;55:270-6.
53. Black PH. Stress and the inflammatory response: A review of neurogenic inflammation. Brain Behav Immun 2002;16:622-53.
54. Culman J, Das G, Ohlendorf C, etal. Blockade of tachykinin NK1/NK2 receptors in the brain attenuates the activation of CRH-neurones in the hypothalamic paraventricular nucleus and the sympathoadrenal and pituitary-adrenal responses to formalin-induced pain in the rat. J Neuroendocrinol 2010;22:467-76.
55. Hirota N, Kuraishi Y, Hino Y, etal. Met-enkephalin and morphine but not dynorphin inhibit noxious stimuli-induced release of substance P from rabbit dorsal horn. Neuropharmacology 1985;24:567-70.
56. Symons FJ, Sutton KA, Walker C, Bodfish JW. Altered diurnal pattern of salivary substance P in adults with developmental disabilities and chronic self-injury. Am J Ment Retard 2003;108:13-8.
57. Schwarz MJ, Späth M, Müller-Bardorff H, etal. Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neurosci Lett 1999;259:196-8.
58. Ikeda T, Minakata H, Nomoto K. The importance of C-terminal residues of vertebrate and invertebrate tachykinins for their contractile activities in gut tissues. FEBS Lett 1999;461:201-4.
59. La J, Kim T, Sung T, etal. Increase in neurokinin-1 receptor-mediated colonic motor response in a rat model of irritable bowel syndrome. World J Gastroenterol 2005;11:237-41.
60. Rupniak NMJ, Kramer MS. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 1999;20:485-90.
61. Lembeck F, Holzer P. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol 1979;310:175-83.
62. Hanf G, Schierhorn K, Brunnée T, etal. Substance P induced histamine release from nasal mucosa of subjects with and without allergic rhinitis. Inflamm Res 2000;49:520-3.
63. Luo W, Sharif TR, Sharif M. Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 1996;56:4983-91.
64. Ruff MR, Wahl SM, Pert CB. Substance P receptor-mediated chemotaxis of human monocytes. Peptides 1985;6(suppl 2):107-11.
65. De Swert KO, Bracke KR, Tine D, Brusselle GG, Joos GF. Role of the tachykinin NK1 receptor in a murine model of cigarette smoke-induced pulmonary inflammation. Respir Res 2009;10:37.
66. Donkin JJ, Turner RJ, Hassan I, etal. Substance P in traumatic brain injury. Prog Brain Res 2007;161:97-109.
67. Masuyama T, Shimizu T. Antinociceptive involvement of substance P in the spinal cord of mice: Dose effects of substance P on the behavior elicited by intrathecally administered NMDA. Brain Res 1997;759:241-6.
68. Block ML, Li G, Qin L, etal. Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: Substance P vs. dynorphin. FASEB J 2006;20:251-8.
69. Reed KL, Heydrick SJ, Aarons CB, etal. A neurokinin-1 receptor antagonist that reduces intra-abdominal adhesion formation decreases oxidative stress in the peritoneum. Am J Physiol Gastrointest Liver Physiol 2007;293:G544-51.
70. Chien C-T, Yu H-J, Lin T-B, Lai M-K, Hsu S-M. Substance P via NK1 receptor facilitates hyperactive bladder afferent signaling via action of ROS. Am J Physiol Renal Physiol 2003;284:F840-51.
71. Springer J, Pleimes D, Scholz FR, Fischer A. Substance P mediates AP-1 induction in A549 cells via reactive oxygen species. Regul Pept 2005;124:99-103.
72. Jing C, Jia-Han W, Hong-Xing Z. Double-edged effects of neuropeptide substance P on repair of cutaneous trauma. Wound Repair Regen 2010;18:319-24.
73. D'Souza M, Garza MA, Xie M, etal. Substance P is associated with heart enlargement and apoptosis in murine dilated cardiomyopathy induced by Taenia crassiceps infection. J Parasitol 2007;93:1121-7.
74. Peters EMJ, Liotiri S, Bodo E, etal. Probing the effects of stress mediators on the human hair follicle: Substance P holds central position. Am J Pathol 2007;171:1872-86.
75. Matsuishi T, Nagamitsu S, Shoji H, etal. Increased cerebrospinal fluid levels of substance P in patients with amyotrophic lateral sclerosis. J Neural Transm 1999;106:943-8.
76. Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. Nature 1983;306:686-8.
77. Dunwiddle T, Lynch G. The relationship between extracellular calcium concentrations and the induction of hippocampal long-term potentiation. Brain Res 1979;169:103-10.
78. Lynch G, Browning M, Bennett W. Biochemical and physiological studies of long-term synaptic plasticity. Fed Proc 1979;38:2117-22.
79. Mantyh PW, Rogers SD, Honore P, etal. Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science 1997;278:275-9.
80. Heath MJ, Womack MD, MacDermott AB. Substance P elevates intracellular calcium in both neurons and glial cells from the dorsal horn of the spinal cord. J Neurophysiol 1994;72:1192-8.
81. Womack MD, MacDermott AB, Jessell TM. Sensory transmitters regulate intracellular calcium in dorsal horn neurons. Nature 1988;334:351-3.
82. Polgár E, Al Ghamdi KS, Todd AJ. Two populations of neurokinin 1 receptor-expressing projection neurons in lamina I of the rat spinal cord that differ in AMPA receptor subunit composition and density of excitatory synaptic input. Neuroscience 2010;167:1192-204.
83. Mease PJ, Choy EH. Pharmacotherapy of fibromyalgia. Rheum Dis Clin North Am 2009;35:359-72.
84. Nässel DR. Neuropeptides in the nervous system of Drosophila and other insects: Multiple roles as neuromodulators and neurohormones. Prog Neurobiol 2002;6:1-84.
85. Conlon JM, Deacon CF, Thorndyke M, Thim L, Faulkner S. Phylogeny of the tachykins. In: Henry JL, Couture R, Cuello AC, etal., eds. Substance P and Neurokinins. New York: Springer-Verlag; 1987:15-7.
86. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. The tachykinin peptide family. Pharmacol Rev 2002;54:285-322.
87. Luo CB, Zheng DR, Guan YL, Yew DT. Localization of substance P and enkephalin by immunohistochemistry in the spinal cord of human fetus. Neuroscience 1988;27:989-93.
88. Luo CB, Zheng DR, Guan YL, etal. Localization of acetylcholinesterase positive neurons and substance P and enkephalin positive fibers by histochemistry and immunohistochemistry in the sympathetic intermediate zone of the developing human spinal cord. Neuroscience 1990;39:97-102.
89. Yew DT, Chan W. Early appearance of acetylcholinergic, serotoninergic, and peptidegic neurons and fibers in the developing human central nervous system. Microsc Res Tech 1999;45:389-400.
90. Tayeb OS, Sastry BVR. Release of substance P, acetylcholine and methionine-enkephalin from mouse cerebral slices: Effects of nicotine. In: Henry JL, Couture R, Cuello AC, etal., eds. Substance P and Neurokinins. New York: Springer-Verlag; 1987:350-2.
91. Sastry BVR. Neuropharmacology of nicotine: Effects on the autoregulation of acetylcholine release by substance P and methionine enkephalin in rodent cerebral slices and toxicological implications. Clin Exp Pharmacol Physiol 1995;22:288-90.
92. Rosas-Ballina M, Tracey KJ. The neurology of the immune system: Neural reflexes regulate immunity. Neuron 2009;64:28-32.
93. Jankovic BD. Neuroimmune interactions: Experimental and clinical strategies. Immunol Lett 1987;16:341-53.
94. Pérez S, Tierney A, Deniau J-M, Kemel M-L. Tachykinin regulation of cholinergic transmission in the limbic/prefrontal territory of the rat dorsal striatum: Implication of new neurokinine 1-sensitive receptor binding site and interaction with enkephalin/mu opioid receptor transmission. J Neurochem 2007;103:2153-63.
95. Williams J, Comisarow J, Day J, Fibiger H, Reiner P. State-dependent release of acetylcholine in rat thalamus measured by in vivo microdialysis. J Neurosci 1994;14:5236-42.
96. Bertrand E, Smadja C, Mauborgne A, Roques B, Daugé V. Social interaction increases the extracellular levels of [Met]enkephalin in the nucleus accumbens of control but not of chronic mild stressed rats. Neuroscience 1997;80:17-20.
97. Stein L, Belluzzi J. Brain endorphins: Possible role in reward and memory formation. Fed Proc 1979;38:2468-72.
98. Dickenson A, Fardin V, Le Bars D, Besson J. Antinociception action following microinjection of methionine-enkephalin in the nucleus raphe magnus of the rat. Neurosci Lett 1979;15:265-70.
99. Harris RE, Clauw DJ, Scott DJ, etal. Decreased central μ-opioid receptor availability in fibromyalgia. J Neurosci 2007;27:10000-6.
100. Yu YJ, Arttamangkul S, Evans CJ, Williams JT, von Zastrow M. Neurokinin 1 receptors regulate morphine-induced endocytosis and desensitization of μ-opioid receptors in CNS neurons. J Neurosci 2009;29:222-33.
101. Jessell T. Substance P in nociceptive sensory neurons. Ciba Found Symp 1982;91:225-48.
102. Helme R, Fletcher J. Substance P in the trigeminal system at postmortem: Evidence for a role in pain pathways in man. Clin Exp Neurol 1983;19:37-44.
103. Oku R, Satoh M, Fujil N, etal. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res 1987;403:350-4.
104. Yunus MB, Masi AT, Calabro J, Miller KA, Feigenbaum S. Primary fibromyalgia (fibrositis): Clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 1981;11:151-71.
105. Vaerøy H, Helle R, Førre Ø, Kåss E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: New features for diagnosis. Pain 1988;32:21-6.
106. Russell IJ, Malcolm DO, Bruce L, etal. Elevated cerebrospinal fluid levels of substance p in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37:1593-601.
107. Alberts K, Bradley L, Alarcón G, etal. Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM) (Abstract). Arthritis Rheum 1996;39(suppl):S212.
108. Stratz T, Fiebich B, Haus U, Müller W. Influence of tropisetron on the serum substance P levels in fibromyalgia patients. Scand J Rheumatol 2004;33:41-3.
109. Reynolds WJ, Inman RD. Plasma substance P levels in fibrositis. J Rheumatol 1988;15:1802-3.
110. Hill R. NK1 (substance P) receptor antagonists-Why are they not analgesic in humans? Trends Pharmacol Sci 2000;21:244-6.
111. Russell IJ. The promise of substance P inhibitors in fibromyalgia. Rheum Dis Clin North Am 2002;28:329-42.
112. Dadabhoy D, Crofford LJ, Spaeth M, Russell IJ, Clauw DJ. Evidence-based biomarkers for fibromyalgia syndrome. Arthritis Res Ther 2008;10:211.
113. Sarchielli P, Alberti A, Floridi A, Gallai V. Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology 2001;57:132-43.
114. Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain 2007;128:209-14.
115. Vink R, van den Heuvel C. Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury. Neurotherapeutics 2010;7:74-80.
116. Alpar EK, Onuoha G, Killampalli VV, Waters R. Management of chronic pain in whiplash injury. J Bone Joint Surg Br 2002;84-B:807-11.
117. Beinborn M, Blum A, Hang L, etal. TGF-beta regulates T-cell neurokinin-1 receptor internalization and function. PNAS 2010;107:4293-8.
118. Margolis KG, Gershon MD. Neuropeptides and inflammatory bowel disease. Curr Opin Gastroenterol 2009;25:503-11.
119. Moldofsky H. The significance of dysfunction of the sleeping/waking brain to the pathogenesis and treatment of fibromyalgia syndrome. Rheum Dis Clin North Am 2009;35:275-83.
120. Andersen ML, Nascimento DC, Machado RB, etal. Sleep disturbance induced by substance P in mice. Behav Brain Res 2006;167:212-8.
121. Holmes A, Heilig M, Rupniak NMJ, Steckler T, Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 2003;24:580-8.
122. Cizza G, Marques AH, Eskandari F, etal. Elevated neuroimmune biomarkers in sweat patches and plasma of premenopausal women with major depressive disorder in remission: The POWER study. Biol Psychiatry 2008;64:907-11.
123. Geracioti TD, Jr, Carpenter LL, Owens MJ, etal. Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry 2006;163:637-43.
124. Crofford L, Demitrack M. Evidence that abnormalities of central neurohormonal systems are key to understanding fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am 1996;22:267-84.
125. Crofford L, Engleberg N, Demitrack M. Neurohormonal perturbations in fibromyalgia. Baillieres Clin Rheumatol 1996;10:365-78.
126. Evengard B, Nilsson CG, Lindh G, etal. Chronic fatigue syndrome differs from fibromyalgia. No evidence for elevated substance P levels in cerebrospinal fluid of patients with chronic fatigue syndrome. Pain 1998;78:153-5.
127. Amital D, Fostick L, Polliack ML, etal. Posttraumatic stress disorder, tenderness, and fibromyalgia syndrome: Are they different entities? J Psychosom Res 2006;61:663-9.
128. Raphael KG, Janal MN, Nayak S. Comorbidity of fibromyalgia and posttraumatic stress disorder symptoms in a community sample of women. Pain Med 2004;5:33-41.
129. Paras ML, Murad MH, Chen LP, etal. Sexual abuse and lifetime diagnosis of somatic disorders: A systematic review and meta-analysis. JAMA 2009;302:550-61.
130. Ruiz-Pérez I, Plazaola-Castaño J, Cáliz-Cáliz R, etal. Risk factors for fibromyalgia: The role of violence against women. Clin Rheumatol 2009;28:777-86.
131. Buskila D, Ablin J, Ben-Zion I, etal. A painful train of events: Increased prevalence of fibromyalgia in survivors of a major train crash. Clin Exp Rheumatol 2009;27(suppl 56):S79-85.
132. Diatchenko L, Slade GD, Nackley AG, etal. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005;14:135-43.
133. Bhatnagar S, Lee TM, Vining C. Prenatal stress differentially affects habituation of corticosterone responses to repeated stress in adult male and female rats. Horm Behav 2005;47:430-8.
134. Foley P, Kirschbaum C. Human hypothalamus-pituitary-adrenal axis responses to acute psychosocial stress in laboratory settings. Neurosci Biobehav Rev 2010;35:91-6.
135. Franklin TB, Russig H, Weiss IC, etal. Epigenetic transmission of the impact of early stress across generations. Biol Psychiatry 2010;68:408-15.
136. Geerse G-J, van Gurp LCA, Wiegant VM, Stam R. Individual reactivity to the open-field predicts the expression of cardiovascular and behavioural sensitisation to novel stress. Behav Brain Res 2006;175:9-17.
137. Zheng P-Y, Feng B-S, Oluwole C, etal. Psychological stress induces eosinophils to produce corticotrophin releasing hormone in the intestine. Gut 2009;58:1473-9.
138. Kuhn TS. The Structure of Scientific Revolutions. Vol 2.Chicago, IL: University of Chicago Press; 1970.
139. Wolfe F. New American College of rheumatology criteria for fibromyalgia: A twenty-year journey. Arthritis Care Res 2010;62:583-4.
140. Wolfe F, Clauw DJ, Fitzcharles M-A, etal. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010;62:600-10.
141. May A. Chronic pain may change the structure of the brain. Pain 2008;137:7-15.
142. Kuchinad A, Schweinhardt P, Seminowicz DA, etal. Accelerated brain gray matter loss in fibromyalgia patients: Premature aging of the brain? J Neurosci 2007;27:4004-7.
143. Rodriguez-Raecke R, Niemeier A, Ihle K, Ruether W, May A. Brain gray matter decrease in chronic pain is the consequence and not the cause of pain. J Neurosci 2009;29:13746-150.
144. Takahashi K, Funata N, Ikuta F, Sato S. Neuronal apoptosis and inflammatory responses in the central nervous system of a rabbit treated with Shiga toxin-2. J Neuroinflammation 2008;5:11.
145. Park S-W, Yan Y-P, Satriotomo I, Vemuganti R, Dempsey RJ. Substance P is a promoter of adult neural progenitor cell proliferation under normal and ischemic conditions. J Neurosurg 2007;107:593-9.
146. Kim S-H, Kim DH, Oh D-H, Clauw DJ. Characteristic electron microscopic findings in the skin of patients with fibromyalgia-A preliminary study. Clin Rheumatol 2008;27:407-11.
147. Hagermark O, Hokfelt T, Pernow B. Flare and itch induced by substance P in human skin. J Investig Dermatol 1978;71:233-5.
148. Theoharides TC, Zhang B, Kempuraj D, etal. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. PNAS 2010;107:4448-53.
149. Littlejohn G, Weinstein C, Helme R. Increased neurogenic inflammation in fibrositis syndrome. J Rheumatol 1987;14:1022-5.
150. Hassett AL, Gevirtz RN. Nonpharmacologic treatment for fibromyalgia: Patient education, cognitive-behavioral therapy, relaxation techniques, and complementary medicine. Rheum Dis Clin North Am 2009;35:393-407.
151. Jones KD, Liptan GL. Exercise interventions in fibromyalgia: Clinical applications from the evidence. Rheum Dis Clin North Am 2009;35:373-91.
152. Ursin H, Eriksen HR. The cognitive activation theory of stress. Psychoneuroendocrinology 2004;29:567-92.
153. Tomaki M, Ichinose M, Miura M, etal. Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis. Am J Resp Crit Care Med 1995;151:613-7.
154. Cohen ML, Quintner JL. Fibromyalgia syndrome, a problem of tautology. Lancet 1993;342:906-9.
155. Wessely S, Hotopf M. Is fibromyalgia a distinct clinical entity? Historical and epidemiological evidence. Best Pract Res Clin Rheumatol 1999;13:427-36.